Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Jun 20. doi: 10.1007/s00277-018-3396-4. [Epub ahead of print]

PMID:
29926156
2.

Validation of the prognostic value of knowledge bank approach to determine AML prognosis in real life.

Huet S, Paubelle E, Lours C, Grange B, Courtois L, Chabane K, Charlot C, Mosnier I, Simonet T, Hayette S, Tigaud I, Thomas X, Salles G, Subtil F, Sujobert P.

Blood. 2018 Jun 4. pii: blood-2018-03-840348. doi: 10.1182/blood-2018-03-840348. [Epub ahead of print] No abstract available.

PMID:
29866812
3.

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).

J Clin Oncol. 2018 Jun 4:JCO2017768192. doi: 10.1200/JCO.2017.76.8192. [Epub ahead of print]

PMID:
29863974
4.

Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.

Paillassa J, Leguay T, Thomas X, Huguet F, Audrain M, Lheritier V, Vianey-Saban C, Acquaviva-Bourdain C, Pagan C, Dombret H, Ifrah N, Boissel N, Hunault-Berger M.

Blood Cancer J. 2018 May 22;8(5):45. doi: 10.1038/s41408-018-0084-5. No abstract available.

5.

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group.

Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P.

Haematologica. 2018 May 24. pii: haematol.2018.193151. doi: 10.3324/haematol.2018.193151. [Epub ahead of print] No abstract available.

6.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 May 10. pii: haematol.2018.189886. doi: 10.3324/haematol.2018.189886. [Epub ahead of print] No abstract available.

7.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Apr 18. doi: 10.1038/s41375-018-0137-6. [Epub ahead of print] No abstract available.

PMID:
29740159
8.

Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.

Collinge E, Loron S, Larcher MV, Elhamri M, Heiblig M, Deloire A, Ducastelle S, Labussière H, Barraco F, Wattel E, Salles G, Paubelle E, Thomas X.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e211-e218. doi: 10.1016/j.clml.2018.02.018. Epub 2018 Mar 2.

PMID:
29572159
9.

Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?

Thomas X, Paubelle E.

Lancet Haematol. 2018 Apr;5(4):e128-e129. doi: 10.1016/S2352-3026(18)30031-0. Epub 2018 Mar 14. No abstract available.

PMID:
29550385
10.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A.

Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22.

11.

Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.

Collinge E, Tigaud I, Balme B, Gerland LM, Sujobert P, Carlioz V, Salles G, Thomas X, Paubelle E.

Medicine (Baltimore). 2018 Feb;97(8):e9657. doi: 10.1097/MD.0000000000009657.

12.

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.

Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, Salles G, Bertrand Y, Michallet M, Thomas X.

World J Stem Cells. 2017 Dec 26;9(12):227-234. doi: 10.4252/wjsc.v9.i12.227.

13.

Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda.

Grateau A, Le Maréchal M, Labussière-Wallet H, Ducastelle-Leprêtre S, Nicolini FE, Thomas X, Morisset S, Michallet M, Ader F; Lyon HEMINF study Group.

Med Mal Infect. 2018 May;48(3):202-206. doi: 10.1016/j.medmal.2017.12.004. Epub 2018 Jan 4.

PMID:
29307444
14.

The management and treatment of acute leukemias in the elderly population.

Thomas X.

Expert Rev Hematol. 2017 Nov;10(11):975-985. doi: 10.1080/17474086.2017.1382345. Epub 2017 Oct 3. Review.

PMID:
28931310
15.

Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.

Quintela A, Sujobert P, Tigaud I, Hayette S, Ffrench M, Salles G, Thomas X, Plesa A.

Oncol Ther. 2017;5(1):111-118. doi: 10.1007/s40487-017-0041-7. Epub 2017 Feb 9.

16.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.

J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.

PMID:
28605290
17.

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

Paubelle E, Zylbersztejn F, Thomas X.

Expert Opin Drug Discov. 2017 Jul;12(7):747-753. doi: 10.1080/17460441.2017.1331215. Epub 2017 May 22. Review.

PMID:
28504025
18.

Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

Cannas G, Poutrel S, Thomas X.

Mediterr J Hematol Infect Dis. 2017 Feb 15;9(1):e2017015. doi: 10.4084/MJHID.2017.015. eCollection 2017. Review.

19.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

20.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
21.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
22.

Novel silicone-based adhesive technology for transdermal therapy systems.

Schalau GK 2nd, Huber RO, Nartker LS, Thomas X.

Ther Deliv. 2017 Apr;8(4):175-178. doi: 10.4155/tde-2016-0085. Epub 2017 Feb 6. No abstract available.

PMID:
28162040
23.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

24.

Treatment of Elderly Patients With Acute Myeloid Leukemia.

Thomas X, Le Jeune C.

Curr Treat Options Oncol. 2017 Jan;18(1):2. doi: 10.1007/s11864-017-0445-5. Review.

PMID:
28144802
25.

Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C.

PLoS One. 2017 Jan 19;12(1):e0170160. doi: 10.1371/journal.pone.0170160. eCollection 2017.

26.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
27.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

J Clin Oncol. 2017 Jan 10;35(2):185-193. Epub 2016 Nov 14.

PMID:
28056203
28.

Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, Salles G, Wattel E, Thomas X.

Ann Hematol. 2017 Mar;96(3):363-371. doi: 10.1007/s00277-016-2899-0. Epub 2016 Dec 23.

PMID:
28011984
29.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

30.

A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia.

Tavernier-Tardy E, Cornillon J, Molucon-Chabrot C, Cahn JY, Tinquaut F, Bourmaud A, Guyotat D, Thomas X.

Hematology. 2017 May;22(4):217-223. doi: 10.1080/10245332.2016.1255372. Epub 2016 Nov 16.

PMID:
27848278
31.

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia.

Heiblig M, Paubelle E, Plesa A, Geay MO, Manzoni D, Gazzo S, Tigaud I, Callet-Bauchu E, Huet S, Salles G, Thomas X, Hayette S, Sujobert P.

Blood. 2017 Jan 5;129(1):128-131. doi: 10.1182/blood-2016-09-741355. Epub 2016 Nov 8. No abstract available.

32.

Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.

Thomas X, Le Jeune C.

Expert Opin Pharmacother. 2016 Dec;17(17):2319-2330. Epub 2016 Oct 31. Review.

PMID:
27759440
33.

Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.

Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber B, Barlev A, Mohty M.

J Med Econ. 2016 Nov;19(11):1034-1039. Epub 2016 Jun 3.

PMID:
27207188
34.

Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.

Heiblig M, Elhamri M, Le Jeune C, Laude MC, Deloire A, Wattel E, Salles G, Thomas X.

Eur J Haematol. 2017 Feb;98(2):134-141. doi: 10.1111/ejh.12811. Epub 2016 Oct 12.

PMID:
27717105
35.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL.

N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.

36.

A molecular epidemiological perspective of rhinovirus types circulating in Amsterdam from 2007 to 2012.

van der Linden L, Bruning AH, Thomas XV, Minnaar RP, Rebers SP, Schinkel J, de Jong MD, Pajkrt D, Wolthers KC.

Clin Microbiol Infect. 2016 Dec;22(12):1002.e9-1002.e14. doi: 10.1016/j.cmi.2016.08.007. Epub 2016 Aug 21.

37.

The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.

Thomas X, Heiblig M.

Expert Opin Drug Discov. 2016 Nov;11(11):1061-1070. Epub 2016 Aug 31. Review.

PMID:
27548716
38.

Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation.

Creidy R, Moshous D, Touzot F, Elie C, Neven B, Gabrion A, Leruez-Ville M, Maury S, Ternaux B, Nisoy J, Luby JM, Héritier S, Dalle JH, Ouachée-Chardin M, Xhaard A, Thomas X, Chevallier P, Souchet L, Treluyer JM, Picard C, Hacein-Bey-Abina S, Dal Cortivo L, Blanche S, Cavazzana M.

J Allergy Clin Immunol. 2016 Sep;138(3):920-924.e3. doi: 10.1016/j.jaci.2016.03.032. Epub 2016 Apr 30. No abstract available.

39.

Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Michallet M, Sobh M, Labussière H, Lombard C, Barraco F, El-Hamri M, Thomas X, Chapuis-Cellier C, Nicolini FE.

Leuk Lymphoma. 2017 Jan;58(1):237-240. Epub 2016 May 31. No abstract available.

PMID:
27243275
40.

Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis.

Barraco F, Labussière-Wallet H, Valour F, Ducastelle-Leprêtre S, Nicolini FE, Thomas X, Ferry T, Dumitrescu O, Michallet M, Ader F; Lyon HEMINF Study Group.

Transpl Infect Dis. 2016 Aug;18(4):595-600. doi: 10.1111/tid.12549. Epub 2016 Jul 5.

PMID:
27203624
41.

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.

Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X.

Leuk Lymphoma. 2017 Jan;58(1):110-117. Epub 2016 May 17.

PMID:
27184036
42.

A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication.

Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Wallet H, Barraco F, Nicolini FE, Thomas X, Gilis L, Chidiac C, Ferry T, Wallet F, Rabodonirina M, Salles G, Michallet M, Ader F; Lyon HEMINF study Group.

Clin Microbiol Infect. 2016 Jul;22(7):636-41. doi: 10.1016/j.cmi.2016.04.025. Epub 2016 May 10.

43.

Occurrence of myelodysplasia/acute myeloid leukemia 'on therapy' in two patients with acute promyelocytic leukemia.

Chelghoum Y, Plesa A, Ducastelle S, Elhamri M, Thomas X.

Indian J Cancer. 2016 Jan-Mar;53(1):59-60. doi: 10.4103/0019-509X.180843. No abstract available.

44.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group.

Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27.

45.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
46.

The safety of treatment options for elderly people with acute myeloid leukemia.

Thomas X, Le Jeune C.

Expert Opin Drug Saf. 2016 May;15(5):635-45. doi: 10.1517/14740338.2016.1161020. Epub 2016 Mar 17. Review.

PMID:
26943698
47.

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.

Le Jeune C, Thomas X.

Drug Des Devel Ther. 2016 Feb 18;10:757-65. doi: 10.2147/DDDT.S83848. eCollection 2016. Review.

48.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

49.

Using EasyMatch® to anticipate the identification of an HLA identical unrelated donor: A validated efficient time and cost saving method.

Dubois V, Detrait M, Sobh M, Morisset S, Labussière H, Giannoli C, Nicolini F, Moskovtchenko P, Mialou V, Ducastelle S, Rey S, Thomas X, Barraco F, Tedone N, Marry E, Garnier F, Bertrand Y, Michallet M.

Hum Immunol. 2016 Nov;77(11):1008-1015. doi: 10.1016/j.humimm.2016.02.004. Epub 2016 Feb 20.

PMID:
26902994
50.

Blinatumomab in acute lymphoblastic leukemia.

Thomas X, Lejeune C.

Expert Rev Anticancer Ther. 2016;16(3):251-3. doi: 10.1586/14737140.2016.1143778. Epub 2016 Feb 6. No abstract available.

PMID:
26775917

Supplemental Content

Loading ...
Support Center